646 related articles for article (PubMed ID: 24357160)
1. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
Asche CV; Hippler SE; Eurich DT
Pharmacoeconomics; 2014 Jan; 32(1):15-27. PubMed ID: 24357160
[TBL] [Abstract][Full Text] [Related]
2. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
7. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Geng J; Yu H; Mao Y; Zhang P; Chen Y
Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
[TBL] [Abstract][Full Text] [Related]
14. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
Yu J; Shah BM; Ip EJ; Chan J
J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
[TBL] [Abstract][Full Text] [Related]
15. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.
Hung A; Jois B; Lugo A; Slejko JF
Am J Manag Care; 2020 Mar; 26(3):e76-e83. PubMed ID: 32181619
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
[TBL] [Abstract][Full Text] [Related]
18. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
19. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.
Tricco AC; Antony J; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
Syst Rev; 2013 Jun; 2():47. PubMed ID: 23810103
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Am J Manag Care; 2019 May; 25(5):231-238. PubMed ID: 31120717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
